U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

SRX3176870: GSM2779607: Y1.7-NSG-Pdl2OE-BRAFi-3; Mus musculus; RNA-Seq
1 ILLUMINA (Illumina HiSeq 3000) run: 29.2M spots, 1.4G bases, 605.3Mb downloads

Submitted by: NCBI (GEO)
Study: Expression changes in YUMM1.7 melanoma with/without PD-L2 overexpression under BRAFi treatment in NSG mice [Y1.7.FPKM.batch4]
show Abstracthide Abstract
Treatment of advanced V600BRAF mutant melanoma using a BRAF inhibitor (BRAFi) or its combination with a MEKi typically elicits partial responses. We compared the transcriptomes of patient-derived tumors regressing on MAPKi therapy against MAPKi-induced temporal transcriptomic states in human melanoma cell lines or murine melanoma in immune-competent mice. Despite heterogeneous dynamics of clinical tumor regression, residual tumors displayed highly recurrent transcriptomic alterations and enriched processes, which were also observed in MAPKi-selected cell lines (implying tumor cell-intrinsic reprogramming) or in bulk mouse tumors (and the CD45-negative or -positive fractions,, implying tumor cell-intrinsic or stromal/immune alterations, respectively). Tumor cell-intrinsic reprogramming attenuated MAPK-dependency, while enhancing mesenchymal, angiogenic and IFN-inflammatory features and growth/survival dependence on multi-RTKs and PD-L2. In the immune compartment, PD-L2 upregulation in CD11c+ immunocytes drove the loss of T-cell inflammation and promoted BRAFi resistance. Thus, residual melanoma early on MAPKi therapy already displays potentially exploitable adaptive transcriptomic, epigenomic, immune-regulomic alterations. Overall design: YUMM1.7 melanoma tumors in NOD/SCID mice with and without PD-L2 expression in baseline (vehicle treated) and BRAFi resistance were sent for transcriptomic analysis by single end 1x50bp HiSeq 3000 RNAseq analysis
Sample: Y1.7-NSG-Pdl2OE-BRAFi-3
SAMN07629782 • SRS2506565 • All experiments • All runs
Organism: Mus musculus
Library:
Instrument: Illumina HiSeq 3000
Strategy: RNA-Seq
Source: TRANSCRIPTOMIC
Selection: cDNA
Layout: SINGLE
Construction protocol: QIAGEN RNeasy micro kit TruSeq RNA Sample Preparation Kit v2, unstranded Poly A transcript enrichment, paired end RNAseq
Experiment attributes:
GEO Accession: GSM2779607
Links:
Runs: 1 run, 29.2M spots, 1.4G bases, 605.3Mb
Run# of Spots# of BasesSizePublished
SRR602640929,172,7221.4G605.3Mb2017-09-13

ID:
4478721

Supplemental Content

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...